收费全文 | 476642篇 |
免费 | 88228篇 |
国内免费 | 22418篇 |
耳鼻咽喉 | 6196篇 |
儿科学 | 9776篇 |
妇产科学 | 6237篇 |
基础医学 | 52097篇 |
口腔科学 | 14772篇 |
临床医学 | 75328篇 |
内科学 | 89129篇 |
皮肤病学 | 13263篇 |
神经病学 | 38759篇 |
特种医学 | 17476篇 |
外国民族医学 | 159篇 |
外科学 | 61630篇 |
综合类 | 55370篇 |
现状与发展 | 120篇 |
一般理论 | 49篇 |
预防医学 | 37810篇 |
眼科学 | 11475篇 |
药学 | 38773篇 |
295篇 | |
中国医学 | 19125篇 |
肿瘤学 | 39449篇 |
2024年 | 1690篇 |
2023年 | 9265篇 |
2022年 | 12846篇 |
2021年 | 19070篇 |
2020年 | 21107篇 |
2019年 | 21648篇 |
2018年 | 24828篇 |
2017年 | 25805篇 |
2016年 | 26231篇 |
2015年 | 31256篇 |
2014年 | 37202篇 |
2013年 | 37936篇 |
2012年 | 31125篇 |
2011年 | 33562篇 |
2010年 | 31662篇 |
2009年 | 27408篇 |
2008年 | 23124篇 |
2007年 | 21219篇 |
2006年 | 21778篇 |
2005年 | 19511篇 |
2004年 | 13220篇 |
2003年 | 12317篇 |
2002年 | 10634篇 |
2001年 | 9632篇 |
2000年 | 8757篇 |
1999年 | 8581篇 |
1998年 | 6234篇 |
1997年 | 6027篇 |
1996年 | 5190篇 |
1995年 | 4676篇 |
1994年 | 3556篇 |
1993年 | 2494篇 |
1992年 | 2819篇 |
1991年 | 2377篇 |
1990年 | 1914篇 |
1989年 | 1701篇 |
1988年 | 1590篇 |
1987年 | 1330篇 |
1986年 | 1146篇 |
1985年 | 849篇 |
1984年 | 634篇 |
1983年 | 567篇 |
1982年 | 399篇 |
1981年 | 369篇 |
1980年 | 254篇 |
1979年 | 217篇 |
1978年 | 194篇 |
1977年 | 184篇 |
1974年 | 140篇 |
1972年 | 139篇 |
Background
Limited data exists demonstrating the efficacy of minimally invasive surgery (MIS) compared to median sternotomy (MS) for multiple valvular disease (MVD). This systematic review and meta-analysis aims to compare operative and peri-operative outcomes of MIS vs MS in MVD.Methods
PubMed, Ovid, and Embase were searched from inception until August 2019 for randomized and observational studies comparing MIS and MS in patients with MVD. Clinical outcomes of intra- and postoperative times, reoperation for bleeding and surgical site infection were evaluated.Results
Five observational studies comparing 340 MIS vs 414 MS patients were eligible for qualitative and quantitative review. The quality of evidence assessed using the Newcastle-Ottawa scale was good for all included studies. Meta-analysis demonstrated increased cardiopulmonary bypass time for MIS patients (weighted mean difference [WMD], 0.487; 95% confidence interval [CI], 0.365-0.608; P < .0001). Similarly, aortic cross-clamp time was longer in patients undergoing MIS (WMD, 0.632; 95% CI, 0.509-0.755; P < .0001). No differences were found in operative mortality, reoperation for bleeding, surgical site infection, or hospital stay.Conclusions
MIS for MVD have similar short-term outcomes compared to MS. This adds value to the use of minimally invasive methods for multivalvular surgery, despite conferring longer operative times. However, the paucity in literature and learning curve associated with MIS warrants further evidence, ideally randomized control trials, to support these findings.2. Firstly, cell viability and biochemical indicators were determined and the cell morphology was observed to confirm the cell injury and develop a cell hepatotoxicity model. Then, with the help of cell metabolomics based on UPLC-MS, the Genkwa Flos group samples were completely separated from the blank group samples in the score plots and seven upregulated as well as two down-regulated putative biomarkers in the loading plot were identified and confirmed. Besides, two signal molecules and four enzymes involved in biosynthesis pathway of lysophosphatidylcholine and the sphingosine kinase/sphingosine-1-phosphate pathway were determined to investigate the relationship between Genkwa Flos hepatotoxicity and these two classic pathways. Finally, the metabolic pathways related to specific biomarkers and two classic metabolic pathways were analyzed to explain the possible mechanism of Genkwa Flos hepatotoxicity.
3. Based on the results, lipid peroxidation and oxidative stress, phospholipase A2/lysophosphatidylcholine pathway, the disturbance of sphingosine-1-phosphate metabolic profile centered on sphingosine kinase/sphingosine-1-phosphate pathway and fatty acid metabolism might be critical participators in the progression of liver injury induced by Genkwa Flos. 相似文献
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.